Trevena, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
  • Pipeline
    • Overview
    • TRV250
    • TRV734
    • TRV045
    • TRV027
  • Products
    • OLINVYKâ„¢ (oliceridine) injection
  • Medical Affairs
    • Investigator-Initiated Trials
    • Contact Medical Information
  • Publications
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Financial Info
    • Stock Info
    • Resources
    • Governance
  • Careers
  • Contact

Press Releases

Investors

Investors

  • Overview
  • Press Releases
  • Events & Presentations
    • Presentations
    • IR Calendar
  • Financial Info
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Stock Info
    • Quote
    • Analyst Coverage
  • Resources
    • Email Alerts
    • Contacts
    • FAQ
  • Governance
    • Overview
    • Management Team
    • Board of Directors
    • Governance Documents

Trevena announces completion of leadership transition and appointment of new director

Oct 01, 2018 7:00am EDT

Trevena to Present Oliceridine, a Next Generation IV Opioid for the Management of Moderate to Severe Acute Pain, at FDA Advisory Committee Meeting on October 11, 2018

Sep 10, 2018 4:01pm EDT

Trevena to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

Aug 30, 2018 4:30pm EDT

Trevena Reports Second Quarter 2018 Financial Results

Aug 02, 2018 7:00am EDT

Trevena announces successful completion of Phase 1 study of TRV250 for acute migraine

Jun 28, 2018 4:01pm EDT

Trevena Expands Commercial and Medical Affairs Leadership Teams with Key Hires

Jun 11, 2018 4:01pm EDT

Trevena to Present at the Jefferies Global Healthcare Conference

May 30, 2018 4:01pm EDT

Trevena announces presentations at the American Society of Colon and Rectal Surgeons 2018 Annual Scientific Meeting

May 22, 2018 7:00am EDT

Trevena Appoints Mark A. Demitrack, M.D., as Chief Medical Officer

May 21, 2018 5:13pm EDT

Trevena Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

May 08, 2018 4:01pm EDT
RSS
  • Prev
    • 1...
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • ...25
    Next
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed
    © 2021 Trevena, Inc. All Rights Reserved.
    Privacy Policy Terms of Use Disclaimer Sitemap